SCHEMBL31662017

SCHEMBL31662017

COc1nc(Cl)cc2nc(SC)nc(NCCO[Si](C)(C)C(C)(C)C)c12

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31662215 0.79
SCHEMBL31661998 0.75
SCHEMBL31662089 0.73 LMNA (0.31) L3MBTL1
SCHEMBL31527485 0.72
SCHEMBL31661979 0.69
SCHEMBL31662039 0.69 LMNA (0.31) L3MBTL1
SCHEMBL31662081 0.69 KMT2A (0.37) MAPK1L3MBTL1ALDH1A1
SCHEMBL31662348 0.68
SCHEMBL24669086 0.66 HTT (0.47) ALDH1A1
SCHEMBL24669084 0.66 ALDH1A1 (0.42) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151594-A1 FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-07-17 WO disclosed